Meena Bansal, MD
Hepatology · New York, NYNPI 1962432476
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $183,359 of the $208,370 with a category attached, or 88.0%. Novo Nordisk accounts for 62.1% of it on its own, with 13 other manufacturers making up the rest.
Across 140 payments — averaging $1488.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$129K
- Boehringer Ingelheim$42K
- GSK$18K
- Madrigal Pharmaceuticals$7K
- Theratechnologies Inc.$5K
- Amarin Pharma, Inc.$2K
- plus $5K from 8 others
Across 174 payments — averaging $3868.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Madrigal Pharmaceuticals$270K
- Intercept Pharmaceuticals, Inc.$127K
- AbbVie$113K
- Siemens Medical Solutions USA, Inc.$84K
- GSK$36K
- Intercept Pharma Europe Ltd.$28K
- plus $14K from 1 others
What the payments were for
- Consulting fees$183,35988%
- Speaking & faculty fees$7,6004%
- Travel & lodging$12,5036%
- Food & beverage$4,8592%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $129,309 |
| Boehringer Ingelheim | 27 | $42,218 |
| GSK | 8 | $17,806 |
| Madrigal Pharmaceuticals | 15 | $7,167 |
| Theratechnologies Inc. | 3 | $5,049 |
| Amarin Pharma, Inc. | 1 | $2,200 |
| Pfizer | 1 | $1,800 |
| Merck | 8 | $1,688 |
| Intercept Pharmaceuticals, Inc. | 3 | $403 |
| Gilead | 10 | $326 |
| AbbVie(2 entities) | 3 | $173 |
| Stryker | 1 | $150 |
| Johnson & Johnson | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$208,370 in reported general payments places this provider in the 80th percentile of 29 hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 17 | $390,432 |
| OcalivaObeticholic Acid | 14 | $208,675 |
| XifaxanRifaximin | 12 | $36,344 |
| Ursodiol | 49 | $6,137 |
| Entecavir | 16 | $2,368 |
| Lactulose | 19 | $472 |
| Carvedilol | 23 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $326 | $390,43217 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $403 | $208,67514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 29 hepatology providers in New York.
Other hepatology in New York
- Robert BrownNew York$967K
- Douglas DieterichNew York$830K
- Arun JesudianNew York$828K
- Albert MinNew York$277K
- Tatyana KushnerNew York$181K
- Howard WormanNew York$119K
- Augusto Villanueva RodriguezNew York$33K
- Jawad AhmadNew York$30K
- Joseph OdinNew York$18K
- Jennifer LeongNew York$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.